ECOG-ACRIN EA9161

Primary Category:

Treatment Protocols

Disease Category:

Chronic Lymphocytic Leukemia, Leukemia

Status:

Closed

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

NCT#03701282

Eligible for screening study DCP 001

EA9161 is closed to new accrual effective April 30, 2021.

EA9161 Quality of Life (QOL) component has reach accrual goal.  Therefore,  EFFECTIVE August 5, 2020, the QOL component is closed to new accrual.